Barinthus Biotherapeutics PLC Sponsored ADR (BRNS)
(Delayed Data from NSDQ)
$1.51 USD
+0.04 (2.72%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $1.47 -0.04 (-2.65%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BRNS 1.51 +0.04(2.72%)
Will BRNS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BRNS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BRNS
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
BRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
The Joint Corp. (JYNT) Q4 Earnings and Revenues Top Estimates
Other News for BRNS
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and Barinthus Biotherapeutics (BRNS)
Barinthus Biotherapeutics price target lowered by $3 at H.C. Wainwright, here's why
Barinthus Biotherapeutics price target lowered by $4 at Barclays, here's why
Barinthus Bio cuts 25% of staff amid pipeline shakeup